Glaxosmithkline Share News (GSK)

RBS Posts Loss After Citizens Writedown But Hails Underlying Progress

Howard Davies set to be confirmed as RBS chairman -sources

By Alexander Smith and Lauren Tara LaCapra LONDON/NEW YORK, Feb 25 (Reuters) - Royal Bank of Scotland Group PLC is set to confirm the appointment of Howard Davies as its new chairman on Thursday, a source familiar with the matter told Reuters. Davies, a former top UK regulator who ser

GSK set to complete $20 bln Novartis asset swap next week

LONDON, Feb 25 (Reuters) - GlaxoSmithKline said on Wednesday it expected to conclude a $20 billion-plus three-part asset swap with Novartis in the week commencing March 2, following progress in obtaining clearances for the deal. GSK is forming a consumer health joint venture with Novartis,

GSK will complete Novartis three-way deal by end of next week

UK drugs giant GlaxoSmithKline says it has made "good progress" on regulatory and legal issues towards completion of its deal with Swiss rival Novartis. GSK said it expected to complete the deal next week, just under a year after it was first announced, with the two pharmaceuticals groups trading ov

UPDATE 1-Medicago wins contract to develop Ebola treatments

(Adds details on background, competition) Feb 24 (Reuters) - Canadian drugmaker Medicago said it received a contract from a U.S. federal agency to develop three different potential treatments for Ebola. The company said on Tuesday it would make the antibodies in its Quebec facility fo

UPDATE 1-Novartis AG wins approval to buy GSK cancer drugs, with conditions

(Adds Canada approving deal, details on divestitures, background on three-way deal) WASHINGTON, Feb 23 (Reuters) - Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline's oncology drugs, with conditions, the U.S. Federal Trade Commission said on Monday. Canada's competit

Canada competition bureau approves GlaxoSmithKline/Novartis deal

OTTAWA, Feb 23 (Reuters) - Canada's Competition Bureau on Monday approved a deal between GlaxoSmithKline PLC and Novartis AG, noting in a statement that U.S. authorities had already said the transaction could go ahead. The companies agreed last April to the transaction that includes GSK buy

CORRECTED-Novartis AG wins approval to buy GSK cancer drugs with conditions

(Corrects name of inhibitor in paragraph two to MEK from MIK) WASHINGTON, Feb 23 (Reuters) - Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline's oncology drugs with conditions, the Federal Trade Commission said on Monday. To win approval for the $16 billion deal, Nov

Novartis AG wins approval to buy GSK cancer drugs with conditions

WASHINGTON, Feb 23 (Reuters) - Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline's oncology drugs with conditions, the Federal Trade Commission said on Monday. To win approval for the $16 billion deal, Novartis agreed to divest assets related to its BRAF and MIK inhibitor

Australian regulator says will not oppose GSK, Novartis deals

SYDNEY, Feb 20 (Reuters) - Australia's competition regulator said on Friday it will not oppose a three part deal between Novartis and GlaxoSmithKline to trade more than $20 billion worth of assets, following approval from EU regulators. The companies agreed last April to the transaction tha

FTSE 100 movers: Centrica drops, oil and gas stocks lower

With oil and gas prices plummeting, Centrica took dramatic action by slashing its dividend and future payout policy, warning that earnings for next year will be lower than expected too. Shares in the British Gas owner dropped sharply the company cut its dividend 21% to 19.2p, which will be a "major

Taihua Total Sales Up For 2014 As Price Increase Offsets Lower Harvest

UK WINNERS & LOSERS: Centrica Shares Tumble On Dividend Cut, Warning

UK Dividends Calendar - Week Ahead

UK Dividends Calendar - Week Ahead